featured
Efficacy and Safety of Low-Dose IL-2 Therapy in Patients With Moderate to Severe Bullous Pemphigoid
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of the American Academy of Dermatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy and safety of low-dose Interleukin-2 in the treatment of moderate to severe bullous pemphigoid: a single center perspective-controlled trial
J Am Acad Dermatol 2024 Aug 23;[EPub Ahead of Print], R Xue, G Li, Y Zhou, B Wang, Y Xu, P Zhao, L Teng, J Zheng, H Liu, S Ji, DM Elston, Y LiangFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.